ArticleMedicine2026
Umbilical vein recanalization with a diameter greater than 6.48mm may promote deterioration of liver reserve function: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the clinical characteristics of cirrhotic patients with umbilical vein recanalization (UVR) and explore the effects of UVR on portal hypertension and liver reserve function (LRF). A total of 122 cirrhotic patients were enrolled and stratified into UVR and non-UVR groups based on the presence or absence of UVR. Clinical and laboratory indices, including hepatic biochemical parameters, portal venous system diameters, portal vein thrombosis, portal pressure gradient (PPG), Child-Pugh classification, and Model for End-Stage Liver Disease (MELD) scores, were compared between the 2 groups. Compared with the non-UVR group, patients in the UVR group had significantly lower serum albumin levels (P = .032) and higher levels of aspartate aminotransferase (P = .040) and total bilirubin (P = .014). The UVR group also presented a markedly lower proportion of moderate-to-severe ascites (P = .032), whereas no significant intergroup difference in PPG was detected. Additionally, the UVR group exhibited a significantly higher proportion of Child-Pugh B and C grades (P = .031). Further subgroup analysis demonstrated that patients with a large UVR shunt (umbilical vein diameter > 6.48 mm) had worse Child-Pugh grade (P = .044) and higher MELD scores (P = .010) relative to non-UVR patients. In conclusion, UVR may alleviate moderate-to-severe ascites by reducing superior mesenteric venous pressure. An umbilical vein diameter exceeding 6.48 mm may be a potential risk factor for deteriorated liver reserve function. Although UVR does not significantly decrease portal venous pressure, it may aggravate portal hemodynamic burden and facilitate the progression of liver cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.